Ann: Appendix 4C - quarterly, page-3

Sales for the quarter of $3.03M, up 42.5% from the prior year period

o Growth reflects Cardiocel®’s increasing global availability and traction

o CardioCel® now in 110 centres globally

 Cash balance at 30 September 2015 of $16.7M

 Initiated a key aortic heart valve reconstruction post-market clinical study using CardioCel® at leading global heart centres

 HSV-2 Phase II nearing completion, with interim results due at end of this calendar year

 Manufacturing of the HPV therapeutic vaccine completed in preparation for Ian Frazer’s next HPV product heading into the clinic

 Admedus Vaccines rebrands as Admedus Immunotherapies